Patient Perspectives Regarding Genetic Testing for Familial Hypercholesterolemia

Miles Marchand, MD, a Victoria Chen, BSc, a Mark Trinder, MSc, a,b Lubomira Cermakova, MSc, c and Liam R. Brunham, MD, PhD, FRCPC a,b,c,d

a Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
b Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada
c Healthy Heart Program Prevention Clinic, St. Paul’s Hospital, Vancouver, British Columbia, Canada
d Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada

ABSTRACT
Background: Familial hypercholesterolemia (FH) is a common genetic disorder resulting in high levels of low-density lipoprotein cholesterol and increased risk of atherosclerotic cardiovascular disease. Genetic testing for FH is recommended but is not available in most of Canada. Consequently, there is a paucity of data regarding patient experiences with genetic testing. The objectives of this study were to investigate the attitudes and perspectives of patients with FH who underwent genetic testing.

Methods: We administered an anonymous online survey to participants in the British Columbia Familial Hypercholesterolemia Registry who had undergone research-based genetic testing for FH. The survey included 25 questions and explored patients’ experiences with the genetic testing process, willingness to recommend genetic screening, and motivation to lower cholesterol levels.

Results: Among 183 respondents, 38 (20.7%) had a positive genetic test result, 27 (14.8%) had a negative result, and 118 (64.4%) were awaiting their results. Compared with individuals awaiting their test results, compared with individuals

Heterozygous familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder affecting 1/311 people worldwide.1,2 Patients with FH have high levels of low-density lipoprotein-cholesterol and a markedly increased risk of early onset atherosclerotic cardiovascular disease (CVD), resulting in substantial morbidity and mortality.3,4 Importantly, this risk is modifiable with the use of statins and other lipid-lowering medications.5,6 Thus, diagnosing and treating patients with FH has been recognized as a priority in Canada7 and internationally.6,8

Genetic testing is recommended in national and international guidelines to support the diagnosis of FH, enable cascade screening, and identify patients at the greatest risk of CVD.7,8 However, genetic testing for FH is not readily available in most of Canada. In addition, relatively little is known about the experiences and perceptions of patients who undergo genetic testing for FH in Canada. The objectives of this study were to investigate the attitudes and behaviours of Canadian patients who undergo genetic testing for FH.

Methods

Patients

We included patients in the British Columbia Familial Hypercholesterolemia Registry10 who had a clinical diagnosis...
results, participants with a positive genetic test were more likely to believe lipid-lowering therapy was highly important (74.3% vs 55.4%; \(P = 0.05\)). They were also more likely to strongly agree that a diagnosis of FH was important to them (71.1% vs 46.2%; \(P = 0.008\)), and were more likely to recommend genetic screening to their family members (85.9% vs 72.9%; \(P = 0.04\)).

**Conclusions:** To our knowledge, this is the first study in Canada to explore the perspectives of patients with FH who underwent genetic testing. These results suggest that genetic testing for FH might offer benefits in important patient-centred outcomes.

The questionnaire was distributed via the Qualtrics survey platform (Qualtrics, Provo, UT) to all patients currently registered in the British Columbia Familial Hypercholesterolemia Registry who had undergone genetic testing. Implied, informed consent was provided by all participants. Participants who enrolled were entered into a draw for a chance to win a “FitBit” (FitBit Inc, San Francisco, CA). Participant responses were anonymously completed, and the results were password-protected and only accessible to the authors. Exclusion criteria included patients aged younger than 18 years and those without a valid e-mail address in the Registry’s records. Invitations to participate in the study were sent via e-mail. Reminder e-mails were sent 2 and 4 weeks after the initial invitation. This study was approved by the Research Ethics Board of the Providence Health Care Research Institute.

**Statistical analysis**

A Pearson \(\chi^2\) test was performed to compare prespecified groups of patients, including positive vs negative, positive vs awaiting test results, and received vs awaiting test results. A subgroup analysis was performed to compare other demographic parameters in the population, including age, sex, family history of CVD, and personal history of CVD. Statistical analysis was performed using SPSS Statistics 27 software (IBM Corp, Armonk, NY).

**Results**

We identified 545 eligible patients with a clinical diagnosis of FH to participate in the survey. Of these, 183 (35.6%) responded to the survey. Among survey respondents, 38 (20.7%) had a positive genetic test result, 27 (14.8%) had a negative result, and 118 (64.4%) were awaiting their results at the time of the survey (Fig. 1).

Table 1 shows the demographics of the patient population, stratified according to genetic test result. Of the patients who completed the survey, 71.6% were 55 years of age or older, and 54.1% were female. There were no significant differences in age and ethnicity between the groups, and rates of CVD and cardiac risk factors were similar. There were significantly more women in the positive test group, compared with the negative test and awaiting results groups (73.7% vs 48.1% vs
Perceptions on genetic testing for FH

Patients with a positive genetic test (81.6%) were more likely to perceive genetic testing for patients with high cholesterol as “very important,” compared with patients with a negative test result (59.3%; \(P = 0.03\)) and those still awaiting their test results (56.8%; \(P = 0.006\); Fig. 2A). They also reported a better overall experience with the genetic testing process compared with those with a negative test and still awaiting their results (86.8% vs 65.4% \(P = 0.04\) and vs 52.2% \(P < 0.001\); Fig. 2B).

Compared with patients still awaiting their test results, patients with a positive genetic test were more likely to “strongly agree” that a diagnosis of FH using genetic testing was important to them (71.1% vs 46.2%; \(P = 0.008\); Fig. 2C), and were more likely to recommend genetic screening for FH in their family members (85.9% vs 72.9%; \(P = 0.04\); Fig. 2D). These responses were not statistically different between the positive and negative test groups.

Patients who received a positive test result were also more likely to rank LLT as a highly important factor for cholesterol reduction compared with those awaiting their results (74.3% vs 65.4% \(P = 0.03\)).

Table 1. Patient characteristics

|                          | Total   | Positive test | Negative test | Awaiting results |
|--------------------------|---------|--------------|---------------|------------------|
| **Total Count**          | 183     | 100          | 27            | 118              |
| **Sex**                  |         |              |               |                  |
| Male                     | 84      | 45.9         | 14            | 60               |
| Female                   | 99      | 54.1         | 13            | 58               |
| **Age, years**           |         |              |               |                  |
| 18-24                    | 2       | 1.1          | 0             | 1                |
| 25-34                    | 10      | 5.5          | 0             | 6                |
| 35-44                    | 12      | 6.6          | 3             | 4                |
| 45-54                    | 28      | 15.3         | 3             | 20               |
| 55-64                    | 56      | 30.6         | 10            | 37               |
| 65-74                    | 54      | 29.5         | 9             | 33               |
| 75-84                    | 19      | 10.4         | 2             | 13               |
| 85 or over               | 2       | 1.1          | 0             | 1                |
| **Ethnicity**            |         |              |               |                  |
| African Canadian         | 1       | 0.5          | 0             | 1                |
| Asian                    | 17      | 9.3          | 3             | 11               |
| Caucasian                | 148     | 80.9         | 22            | 95               |
| Hispanic/Latin           | 3       | 1.6          | 0             | 2                |
| Indigenous               | 3       | 1.6          | 1             | 2                |
| South Asian              | 9       | 4.9          | 2             | 6                |
| Other                    | 9       | 4.9          | 3             | 6                |
| **Location**             |         |              |               |                  |
| Lower mainland           | 147     | 80.3         | 25            | 97               |
| Interior BC              | 12      | 6.6          | 4             | 6                |
| Northern BC              | 4       | 2.2          | 3             | 1                |
| Vancouver Island         | 11      | 6.0          | 2             | 9                |
| Other                    | 8       | 4.4          | 4             | 4                |
| No response              | 1       | 0.5          | 0             | 1                |
| **CVD history**          |         |              |               |                  |
| TIA/stroke               | 8       | 4.4          | 2             | 5                |
| MI                       | 18      | 9.8          | 3             | 13               |
| CAD                      | 39      | 21.3         | 8             | 27               |
| PAD                      | 4       | 2.2          | 1             | 3                |
| None                     | 134     | 73.2         | 30            | 85               |
| **Cardiac risk factors** |         |              |               |                  |
| HTN                      | 55      | 30.1         | 8             | 41               |
| DM                       | 12      | 6.6          | 1             | 10               |
| Family history of CVD    | 111     | 60.7         | 14            | 72               |
| Obesity                  | 58      | 31.7         | 8             | 36               |
| CKD                      | 5       | 2.7          | 0             | 4                |
| Smoking                  | 3       | 1.6          | 0             | 2                |
| None                     | 43      | 23.5         | 8             | 22               |

545 patients received email invitation to participate
183 patients (33.6%) completed survey
27 patients (14.8%) with negative genetic test
118 patients (46.4%) awaiting results of genetic testing

Figure 1. Flow diagram of patient population

49.2%; \(P = 0.03\)). Furthermore, fewer patients with a positive test were from the Lower Mainland compared with those with a negative test or awaiting their results (65.8% vs 92.6% vs 82.2%; \(P = 0.03\)).

BC, British Columbia; CAD, coronary artery disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; NS, nonsignificant; PAD, peripheral arterial disease; TIA, transient ischemic attack.

* Multiple answers were allowed for these categories.
patients in the positive group showed nonsignificant differences between self-reported LLT adherence rates. Compared with the negative group, the positive group was more likely to have a high understanding of their diagnosis (19.6% vs 19.7%; P = 0.18) compared with those without CVD (27.1% vs 10.8%; P = 0.007; Fig. 5A). They were also more likely to report high motivation to take LLT (71.1% vs 55.4%; P = 0.04) or to pursue healthy lifestyle behaviours (46.7% vs 44.7%; P = 0.05) and were more likely to recommend genetic testing to their family members (82.7% vs 74.3%; P = 0.04; Fig. 4B), and were more likely to recommend genetic testing to their family members (56.8% vs 46.2%; P = 0.005). They were also more likely to recommend genetic testing to their family members (85.9% vs 72.9%; P = 0.04). These findings suggest that the experience of undergoing genetic testing, rather than the specific result, leads to more positive patient perceptions.

Motivation levels were evaluated on a scale from 0 to 10, with “high motivation” defined as a response of 10 (Fig. 3). There were nonsignificant trends suggesting the positive test group was more likely to be highly motivated to reduce cholesterol levels (54.1% vs 45.1%; P = 0.18), pursue healthy lifestyle behaviours (44.7% vs 36.4%; P = 0.36), and take LLT (71.1% vs 58.9%; P = 0.18) compared with those awaiting their results. Compared with the negative group, the patients in the positive group showed nonsignificant trends toward higher motivation to take LLT (71.1% vs 52.2%; P = 0.12) but lower motivation to engage in healthy lifestyle behaviours (44.7% vs 59.3%; P = 0.25). There were no differences between self-reported LLT adherence rates.

Implications of a genetic diagnosis

There were no significant differences in patients’ understanding of their diagnosis between the 3 groups, although there was a trend suggesting that patients who had received their results (pooled positive and negative) more frequently reported a high understanding of their illness compared with those still awaiting their test results (19.7% vs 12.8%; P = 0.08). No significant differences were noted between groups regarding concerns of the effect of a genetic diagnosis on insurance and employment opportunities.

Subgroup analyses

Patients with a family history of CVD were more likely to report a high understanding of their diagnosis (19.6% vs 8.5%; P = 0.04; Fig. 4A). They were also more likely to believe that genetic testing was “very important” for patients with high cholesterol (68.5% vs 52.8%; P = 0.03; Fig. 4B), and were more likely to recommend genetic testing to their family members (82.7% vs 69.4%; P = 0.04; Fig. 4C).

Similarly, patients with a personal history of CVD reported a high understanding of their diagnosis more frequently than those without CVD (27.1% vs 10.8%; P = 0.007; Fig. 5A). They were also more likely to report high motivation to reduce cholesterol (60.4% vs 41.0%; P = 0.007; Fig. 5B), and were more likely to highly rank LLT as an important factor in achieving cholesterol reduction (71.7% vs 53.9%; P = 0.04; Fig. 5C). However, there were no significant differences in the rate of high motivation to take LLT (66.0% vs 58.6%; P = 0.4) or to pursue healthy lifestyle behaviours (53.1% vs 37.3%; P = 0.06).

Patients aged 55 years and older more frequently reported a high motivation to lower cholesterol (50.8% vs 34.6%; P = 0.05) and pursue healthy lifestyle behaviours (46.6% vs 28.8%; P = 0.03) than those younger than 55 years. They were more likely to highly rank exercise as an important factor for cholesterol reduction (66.4% vs 48.1%; P = 0.02). Older patients were also more likely to report never missing a dose of their LLT (66.9% vs 52.1%; P = 0.05).

Figure 2. Comparison of survey responses on the basis of genetic test results. Comparisons are between participants with a positive test, negative test, or awaiting their test results. Results are shown for responses to questions: (A) How important is genetic testing for patients with high cholesterol? (B) How was your overall experience with the genetic testing process? (C) Diagnosis of FH using genetic testing is important to me. (D) Would you recommend genetic screening for FH in your family members? (E) Relative perceived importance of LLT for cholesterol reduction. (F) Relative perceived importance of exercise for cholesterol reduction. FH, familial hypercholesterolemia; LLT, lipid-lowering therapy.
Men and women did not report any significant differences in motivation to lower cholesterol levels, take LLT, or engage in healthy lifestyle behaviours. However, men reported a higher concern for the implications of genetic testing on their insurance (33.3% vs 17.3%; \( P = 0.01 \)) and statistically nonsignificant higher concern for the implications on their employment (10.8% vs 4.1%; \( P = 0.08 \)).

**Discussion**

To our knowledge, this is the first study in Canada to explore the perspectives and behaviours of patients with FH who underwent genetic testing. Compared with individuals awaiting their test results, participants with a positive genetic test were more likely to believe LLT was a highly important factor to lower their cholesterol levels. They also agreed more strongly that a genetic diagnosis of FH was important and were more likely to recommend genetic screening for their family members. Importantly, most (78.1%) of the participants who had received their results reported a positive overall experience with the genetic testing process. These findings have important implications for the development of genetic testing programs for FH, because individuals with a genetic diagnosis might be more engaged with their care.

Although a number of studies have shown changes in patient behaviour after receiving genetic testing for a variety of diseases,\(^\text{15,16}\) a meta-analysis of 17 studies performed in 2016 did not show any significant behavioural change before and after genetic testing.\(^\text{17}\) In Norway and The Netherlands, several studies have shown increased LLT adherence and physician contact after genetic testing;\(^\text{18–22}\) however, to our knowledge, only 1 study has ever assessed other behavioural
changes in an FH patient population. In their study in the United Kingdom, Marteau et al. did not identify any behavioural differences before and after genetic testing for FH, but participants with a genetic diagnosis believed that diet had a lesser role and LLT had a greater role in reducing cholesterol. Our results corroborate this finding in a Canadian population: participants with a positive genetic test were more likely to rank LLT as a highly important factor to lower cholesterol levels, whereas individuals awaiting the results of their genetic testing were more likely to highly rank exercise. Because FH is significantly undertreated worldwide, genetic testing might be an important tool to engage patients in their treatment and optimize medication use. Despite participants with a positive genetic test perceiving more importance of LLT, there were no differences in motivation to lower cholesterol levels, use LLT, or engage in healthy lifestyle behaviours. There were also no differences in self-reported LLT adherence after genetic diagnosis. This suggests that although patients’ perceptions might change, this might not directly affect their actual motivation or behaviour. This might also reflect the fact that in our study, participants had already received a clinical diagnosis of FH, and had received physician contact and lifestyle counselling before undergoing genetic testing.

Importantly, individuals with a positive genetic test were more likely to recommend genetic screening to their family members. Because of the autosomal dominant inheritance of FH, cascade screening of family members is strongly recommended in the 2018 Canadian Cardiovascular Society’s position statement on FH. Cascade screening relies on index patients informing their family members of their diagnosis or providing a health care provider with their contact information. Without index patient cooperation, cascade screening is challenging, and many patients are diagnosed with FH only after suffering a major cardiovascular event. A genetic diagnosis of FH might increase rates of cascade screening, which, in turn, can allow for early diagnosis of FH and initiation of LLT and lifestyle changes, which have been proven to be effective in CVD prevention. Importantly, our data suggest that genetic testing might help to engage the index patient to facilitate cascade screening of their first-degree relatives.

A genetic diagnosis did not significantly improve patients’ understanding of their illness, but individuals with a personal history or family history of CVD had a significantly better understanding. Because FH is most often a clinically silent disease, patients might find it more difficult to understand unless they or a family member have developed symptomatic CVD as a result. This highlights the need for robust patient education and counselling, especially for individuals who have not experienced clinical sequelae of their diagnosis personally or in a family member. Individuals with a positive family history of CVD also believed that genetic testing was more important and were more likely to recommend genetic testing to their family members, highlighting the importance of thorough family history screening in patients with FH.

Limitations

This study included patients from a single specialized lipid clinic in Canada. Future studies will be needed to extend these observations to other jurisdictions. Because of the relatively small sample size, some of the trends we observed were not statistically significant, but might become significant in a sufficiently large sample. As a result of limited genetic testing infrastructure for FH in Canada, this study used research-based genetic testing and the tests were not performed through an accredited clinical laboratory. Results of genetic testing were returned to participants by physicians with expertise in FH, rather than by certified genetic counsellors. It is possible that patient experiences and perceptions could change on the basis of how the results are communicated.

This reflects the reality in most lipid or cardiology clinics in Canada, in which genetic counselling is not readily available. Furthermore, we did not formally assess the psychometric properties of the survey instrument used, and this survey has not been validated in previous studies; however, our survey

Figure 5. Comparison of survey responses on the basis of personal history of CVD. Comparisons are between participants self-reporting a personal history of CVD or not. Results are shown for responses to questions: (A) How well do you understand your illness? (B) How motivated do you feel to lower your cholesterol? (C) Relative perceived importance of LLT for cholesterol reduction. CVD, cardiovascular disease; LLT, lipid-lowering therapy.
was developed on the basis of those used in previous studies, and in consultation with content area experts. This study was also prone to selection bias, because it relied on patients to voluntarily respond to an online questionnaire. This might have selected for individuals who were more engaged in their care and have a higher socioeconomic status. Finally, our study investigated self-reported perceptions and behaviours, but did not directly evaluate these behaviours, such as medication adherence or true rates of cascade screening, which should be areas of further study.

Conclusions

To our knowledge, this is the first study in Canada to explore the perspectives of patients with FH before and after genetic testing. Compared with individuals awaiting their test results, participants with a positive genetic test were more likely to believe LLT was a highly important factor to lower their cholesterol levels. They also agreed more strongly that a diagnosis of FH was important and were more likely to recommend screening for their family members. Overall, these results suggest that genetic testing for FH might offer benefits in important patient-centred outcomes. These results have important implications for the design and implementation of genetic screening programs for FH in Canada.

Acknowledgements

The authors thank the patients in the British Columbia Familial Hypercholesterolemia Registry for their participation in this research.

Funding Sources

This study was supported by Genome British Columbia (SIP008 to L.R.B.). A patient engagement forum at which this study was discussed was funded by a Michael Smith Foundation for Health Research Reach Award (to L.R.B.). L.R.B. is a Michael Smith Foundation for Health Research Scholar and is a Canada Research Chair in Precision Cardiovascular Disease Prevention.

Disclosures

The authors have no conflicts of interest to disclose.

References

1. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 2020;75:2553-66.
2. Hu P, Dharmayat Kl, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 2020;141:1742-59.
3. Gidding SS, Ann Champagne M, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015;132:2167-92.
4. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97:3956-64.
5. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolaemia. N Engl J Med 2019;381:1547-56.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34. 3478-90a.
7. Brunham LR, Iuel I, Aljenedil S, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can J Cardiol 2018;34:1553-63.
8. Representatives of the Global Familial Hypercholesterolaemia Commu-

ity, Wilemon KA, Patel J, et al. Reducing the clinical and public health burden of familial hypercholesterolaemia: a global call to action. JAMA Cardiol 2020;5:217-29.
9. Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolaemia: JACC Scientific Expert Panel. J Am Coll Cardiol 2018;72:662-80.
10. Wong S, Taraboanta C, Francis GA, Ignaszewski A, Froschlich J. The British Columbia Familial Hypercholesterolemia Registry. B C Med J 2013;55:326-30.
11. Trinder M, Li X, DeCastro ML, et al. Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolaemia. J Am Coll Cardiol 2019;74:512-22.
12. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018;46:D1062-7.
13. Marteau T, Senior V, Humphries SE, et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 2004;128A:285-93.
14. Moss-Morris R, Weinman J, Petrie K, et al. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002;17:1-16.
15. Barron-Chase AM, Hovick SR, Peterson SK, et al. Changes in screening behaviors and attitudes toward screening from pre-test genetic counseling to post-disclosure in Lynch syndrome families. Clin Genet 2013;83:215-20.
16. Larouche G, Chiquette J, Pelletier S, Simard J, Dorval M. Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? Fam Cancer 2017;16:35-40.
17. Hollands GJ, French DP, Griffen SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 2016;352:i1102.
18. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8.
19. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolaemia. Arch Intern Med 2003;163:65-8.
20. Leren TP, Manshaa T, Skovholt U, et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway.
results from a family-based screening program. Semin Vasc Med 2004;4:75-85.

21. Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010;5:e9220.

22. Avis HJ, Kusters DM, Vissers MN, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr 2012;161:99-103.

23. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.

24. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008;29:2625-33.